A Safety and efficacy study of febuxostat, a non-purine-selective inhibitor of xanthine oxidase, for prevention of tumor lysis syndrome in patients with hematological malignancies.

A Safety and efficacy study of febuxostat, a non-purine-selective inhibitor of xanthine oxidase, for prevention of tumor lysis syndrome in patients with hematological malignancies. - A Safety and efficacy study of febuxostat, a non-purine-selective inhibitor of xanthine oxidase, for prevention of tumor lysis syndrome in patients with hematological malignancies.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007538

Enrollment

Registered

2012-05-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hematological malignancies who develop tumor lysis syndrome

Interventions

febuxostat 60 mg/day orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with hematological malignancies who will receive chemotherapy and develop tumor lysis syndrome.

Exclusion criteria

Exclusion criteria: impared hepatic function renal dysfunction diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Determine urate-lowering efficacy (the target urate level of 7.5 mg/dl) in patients developing tumor lysis syndrome.	—

Secondary

Measure	Time frame
Safety in using febuxostat in patients with hematological malignancies developing tumor lysis syndrome.	—

Countries

Japan

Contacts

Public ContactTakahiro Yamauchi

Univ. of Fukui Department of Hematology and Oncology

tyamauch@u-fukui.ac.jp+81776613111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026